David Moskowitz on 8VC's Bio-IT Investments
David Moskowitz sits down with Daniel Haders II, Ph.D. in Episode 2 of our four-part series to discuss 8VC's Bio-IT investments; and why the firm values operating experience and action, but also new ideas and creative theories. David will touch on the firms unique blend of strengths and worldviews, and how this enables 8VC to model investment opportunities using multiple frameworks to help companies succeed in unparalleled ways.
In Today’s Episode You Will Learn
How does David define the Bio-IT space, what commonalities and unifying themes does he see within 8VC’s existing Bio-IT portfolio?
What is 8VC’s primary mandate within biotechnology? With the firm’s investments spanning a broad spectrum, how does David think about the investing throughout the entire value chain and accelerating the sector?
8VC’s mantra is, “The world's broken, let's fix it” how does this statement inform David’s view of the world, and his appetite for risk as an investor?
David Moskowitz focuses on the Bio-IT space. Prior to joining 8VC, David completed his Ph.D. in Biomedical Informatics at Stanford University, where he concurrently received an M.S. in Statistics. His research focused on the development of statistical and machine learning approaches for analyzing genomics data, and the characterization of epigenetic changes associated with aging in T cells. Previously, David was a Bioinformatic Analyst at Einstein College of Medicine, where he worked on the genetics of aging and human disease. He performed his undergraduate studies in Computational Biology at Brown University.
